Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, approved for treatment of IDH1-mutant (mIDH1) acute myeloid leukemia (AML). Preclinical work suggested that addition of azacitidine to ivosidenib enhances mIDH1 inhibition–related differentiation and apoptosis. P...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: DiNardo, Courtney D., Stein, Anthony S., Stein, Eytan M., Fathi, Amir T., Frankfurt, Olga, Schuh, Andre C., Döhner, Hartmut, Martinelli, Giovanni, Patel, Prapti A., Raffoux, Emmanuel, Tan, Peter, Zeidan, Amer M., de Botton, Stéphane, Kantarjian, Hagop M., Stone, Richard M., Frattini, Mark G., Lersch, Frederik, Gong, Jing, Gianolio, Diego A., Zhang, Vickie, Franovic, Aleksandra, Fan, Bin, Goldwasser, Meredith, Daigle, Scott, Choe, Sung, Wu, Bin, Winkler, Thomas, Vyas, Paresh
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2021
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7771719/
https://ncbi.nlm.nih.gov/pubmed/33119479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01632
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires